Integrated lipidomics and transcriptomics reveal the key role of ceramides in the development of endometriosis.

Authors

Shanshan Mei, Nan Ding, Mengyi Cheng, Chen Zhang, Jinli Miao, Mengli Liu, Xiaojun Shi, Xinyan Wang

Published in

Molecular human reproduction. Aug 11, 2026. Epub Aug 11, 2026.

Abstract

Endometriosis (EMs) is a chronic gynecological disease with poorly understood pathogenesis. This study integrated lipidomics and transcriptomics to systematically investigate aberrant sphingolipid metabolism in EMs, aiming to identify pathogenic mechanisms and therapeutic targets. Differential metabolites and genes in EMs lesions were identified through multi-omics profiling, followed by gene-metabolite network construction via MetaboAnalyst. EMs mouse models were established by intraperitoneal endometrial transplantation. Mice received ceramide or EMs therapeutics for two weeks. Lesion size, cytokines, ceramide levels, apoptosis, SMPD3 expression, and CD206+ macrophage infiltration were assessed using ELISA, TUNEL, Western blot, RT‑qPCR, flow cytometry, and dual immunofluorescence. Integrated analysis revealed substantial metabolic and transcriptional alterations in EMs lesions. Sphingomyelin (SM) emerged as a central network hub, while ceramide (Cer), generated via SMPD3-mediated SM hydrolysis, was markedly accumulated in lesions. In vivo, exogenous Cer(d18:1/20:0) supplementation exacerbated ceramide accumulation, enhanced anti-apoptotic capacity, intensified inflammatory responses, and promoted CD206+ macrophages infiltration. Conversely, effective EMs therapeutics suppressed ceramide accumulation, downregulated macrophage SMPD3 expression, and reduced CD206+ macrophages infiltration. Collectively, we identify the SM-SMPD3-Cer axis as a novel metabolic driver of EMs progression. Pathological ceramide accumulation facilitates lesion development by promoting inflammation, enhancing CD206+ macrophages polarization, and suppressing apoptosis. These findings provide new metabolic insights and a theoretical foundation for ceramide-targeted therapeutic strategies in endometriosis.

PMID:
42581578
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.